[Federal Register Volume 65, Number 79 (Monday, April 24, 2000)]
[Notices]
[Pages 21770-21771]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-10177]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Invention; Availability for Licensing: 
``Prostate Cancer Therapeutic and in vitro Diagnostic Method to Screen 
for the Presence of Metastatic Prostate Cancer--A Monoclonal Antibody 
Specific to Prostate Cells''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development.

ADDRESSES: Licensing information may be obtained by contacting J. R. 
Dixon, Ph.D., at the Office of Technology Transfer, National Institutes 
of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 
20852-3804 (telephone 301/496-7056 ext 206; fax 301/402-0220; E-Mail: 
<a href="/cdn-cgi/l/email-protection#aec4ca9c9f9cc9eee0e7e680e9e1f8"><span class="__cf_email__" data-cfemail="6e040a5c5f5c092e20272640292138">[email protected]</span></a>). A signed Confidential Disclosure Agreement is required 
to receive a copy of any patent application.

SUPPLEMENTARY INFORMATION:
    Invention Title: ``Monoclonal Antibodies to Prostate Cells''.
    Inventor: Dr. Ira H. Pastan (NCI).
    USP SN: 5,489,525 [= DHHS Ref. No. E-201-92/0]--Issued on February 
6, 1996.

Abstract

    Prostate Cancer is a disease affecting approximately 1 million men 
in the U.S.A., with an annual incidence of around 179,000 and 
approximately 30,000 deaths per year. It is estimated that one-third of 
men over 50 will develop prostate cancer at some time in their lives. 
Control of primary tumor by surgical resection and/or radiation has 
proven effective in a number of cases, however, metastatic spread, 
primarily to the bone, especially at late hormone independent stages of 
the disease, has been more difficult to control and monitor. With the 
aging of the U.S. population, it has been estimated that the number of 
prostate cancer cases will increase dramatically.

Technology

    The technology disclosed in the 5,489,525 patent relates to a 
monoclonal antibody which is capable of binding to a cell surface 
differentiation antigen

[[Page 21771]]

specific for prostate adenocarcinomas and other prostate cancer cells. 
Accordingly, methods of therapy can be employed with this monoclonal 
antibody to destroy prostate cancer cells, and hence, this monoclonal 
antibody may be useful in therapy and/or the diagnosis of prostate 
cancer. This monoclonal antibody can be produced by recombinant DNA 
techniques, the host cell being a eucaryotic or procaryotic cell, 
preferably a eucaryotic cell and more preferably mammalian. Hence, a 
monoclonal antibody, a recombinant monoclonal antibody, single 
polypeptide binding molecules, and binding fragments thereof coupled to 
molecules which are cytotoxic to prostate cancer cells (e.g., 
chemotherapeutic agents, prodrugs, cytotoxic or inhibitory peptides, 
cytokines, enzymes, diphtheria toxin, Pseudomonas Exotoxin, etc.) could 
be used to develop a prostate cancer therapeutic or diagnostic test 
system.
    The above mentioned Invention and technology are available for 
licensing.

    Dated: April 18, 2000.
Jack Spiegel,
Director, Division of Technology Development & Transfer, Office of 
Technology Transfer.
[FR Doc. 00-10177 Filed 4-21-00; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>